Karyopharm Therapeut (KPTI) Stock Price, Quote & News

Company Profile

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compounds include XPOVIO in combination with bortezomib and dexamethasone for th...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 658 0600

Website: www.karyopharm.com

Address:

85 Wells Avenue, 2nd Floor, Suite 210, Newton, United States

celebratelife Apr. 9 at 4:18 AM

$KPTI $XBI the crooks have a long history of running KPTI up to short into. Trend in short history proves it. They're experts with playing with psychology "is this is?" "this is THE run that will take it to the moon". Richard Paulson, Barry Greene, Mike Mano and the rest of the useless Board continue to get big bucks in their accounts while they've destroyed KPTI and turned it into a bitch for wall street crooks / cockroaches / vultures. Not to mention selling us out through dilution for pennies on the dollar after they killed KPTI by 99%, and toxic financing which gave them more money to continue the vacation club splurging culture that included giving away money we don't have , e.g., multiple 200k+ donations of the money we don't have to Patrick Dempsey center, etc., etc., one long painful history of how they've constantly betrayed shareholders and fucked us up as they continued getting big money despite piss poor performance. Te 5yr chart illustrates what Paulson et al. are about.

0 · Reply

hegdaom Apr. 9 at 3:24 AM

$KPTI

0 · Reply

hegdaom Apr. 9 at 3:24 AM

$KPTI $XBI

0 · Reply

ripztrip Apr. 9 at 1:18 AM

$KPTI This is running out of steam. Without big buyers this & next week, IMHO it's back at five or below soon! $XBI

0 · Reply

hegdaom Apr. 8 at 11:42 AM

$KPTI 5 or more years of dilution.

0 · Reply

hegdaom Apr. 8 at 6:14 AM

$KPTI Went up 36% in 5 sessions

0 · Reply

hegdaom Apr. 8 at 1:18 AM

$KPTI

1 · Reply

InkaTwits Apr. 7 at 6:29 PM

$KPTI 🤷‍♂️

0 · Reply

hbkstockislife Apr. 7 at 5:41 PM

$KPTI everyday up

1 · Reply

hegdaom Apr. 7 at 5:30 PM

$KPTI Any updates today?

0 · Reply

Karyopharm Therapeutics Falls As Pivotal Trial Hits Spleen Goal But Misses Symptom Mark

Mar 24, 2026, 7:17 AM EDT - 15 days ago

Karyopharm Therapeutics' blood cancer drug meets one of two main goals in study

Mar 24, 2026, 7:01 AM EDT - 15 days ago

Karyopharm Announces $30 Million Private Placement with RA Capital

Mar 24, 2026, 7:00 AM EDT - 15 days ago

Karyopharm's Phase 3 SENTRY Trial in Myelofibrosis Met First Co-Primary Endpoint, Demonstrating Statistically Significant Improvement in Spleen Volume Reduction

Mar 2, 2026, 4:05 PM EST - 5 weeks ago

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Feb 12, 2026, 7:30 AM EST - 7 weeks ago

Karyopharm Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress

Feb 5, 2026, 7:30 AM EST - 2 months ago

Karyopharm to Report Fourth Quarter and Full Year 2025 Financial Results on February 12, 2026

Jan 12, 2026, 7:00 AM EST - 3 months ago

Karyopharm Announces Preliminary Unaudited 2025 Revenue and Reiterates Expectation of Delivering Potentially Transformative Phase 3 Data in 2026

Dec 8, 2025, 7:00 AM EST - 4 months ago

Karyopharm to Participate in Baird's Biotech Discovery Series

Dec 1, 2025, 7:00 AM EST - 4 months ago

Karyopharm to Participate at the Piper Sandler 37th Annual Healthcare Conference

Nov 3, 2025, 7:00 AM EST - 5 months ago

Karyopharm Reports Third Quarter 2025 Financial Results and Highlights Recent Company Progress

Oct 27, 2025, 7:00 AM EDT - 5 months ago

Karyopharm to Report Third Quarter 2025 Financial Results on November 3, 2025

Oct 8, 2025, 1:31 PM EDT - 6 months ago

Karyopharm Strengthens Balance Sheet With $100 Million Financing To Extend Cash Runway Into 2026

Oct 8, 2025, 7:00 AM EDT - 6 months ago

Karyopharm Announces Strategic Financing Transactions to Support Growth; Extends Cash Runway Into Second Quarter of 2026, Beyond Expected Top-Line Readout of Phase 3 SENTRY Trial in Myelofibrosis

Sep 10, 2025, 7:00 AM EDT - 7 months ago

Karyopharm Announces Completion of Enrollment in the Phase 3 SENTRY Trial in Myelofibrosis

Aug 11, 2025, 7:30 AM EDT - 8 months ago

Karyopharm Reports Second Quarter 2025 Financial Results and Highlights Recent Company Progress

Aug 5, 2025, 7:00 AM EDT - 8 months ago

Karyopharm to Report Second Quarter 2025 Financial Results on August 11, 2025

Jun 3, 2025, 8:00 AM EDT - 11 months ago

Karyopharm to Present at the Jefferies Global Healthcare Conference

May 19, 2025, 7:00 AM EDT - 11 months ago

Karyopharm to Participate at the 2025 RBC Capital Markets Global Healthcare Conference

May 14, 2025, 9:31 AM EDT - 11 months ago

Karyopharm Announces Poster Presentation on Selinexor in Myelofibrosis at the 2025 European Hematology Association Annual Meeting

May 13, 2025, 1:39 PM EDT - 11 months ago

These Analysts Revise Their Forecasts On Karyopharm Therapeutics After Q1 Results

May 12, 2025, 4:05 PM EDT - 11 months ago

Karyopharm Reports First Quarter 2025 Financial Results and Announces New Data in Myelofibrosis that Further Suggests Selinexor May Lead to Meaningful Spleen Volume Reduction, Symptom Improvement, Hemoglobin Stabilization and Disease Modification

May 8, 2025, 4:05 PM EDT - 11 months ago

Karyopharm to Report First Quarter 2025 Financial Results on May 12, 2025

Mar 5, 2025, 12:00 AM EST - 1 year ago

XPOVIO® (selinexor) Approved for Commercialization in Indonesia, Further Expanding Antengene's Commercial Presence in APAC

Feb 24, 2025, 8:40 AM EST - 1 year ago

Karyopharm Announces 1-for-15 Reverse Stock Split

Feb 19, 2025, 7:30 AM EST - 1 year ago

Karyopharm Reports Fourth Quarter and Full Year 2024 Financial Results, Announces Update to Phase 3 XPORT-EC-042 Trial and Highlights Recent Company Progress

Feb 13, 2025, 4:30 AM EST - 1 year ago

Antengene Announces XPOVIO® Approved for Public Health Insurance Coverage in Taiwan Market, Benefiting More Patients with R/R MM in the Region

Feb 12, 2025, 7:00 AM EST - 1 year ago

Karyopharm to Report Fourth Quarter and Full Year 2024 Financial Results on February 19, 2025

Jan 13, 2025, 8:30 AM EST - 1 year ago

Karyopharm Announces Preliminary Unaudited 2024 Revenue and 2025 Objectives

Jan 2, 2025, 7:00 AM EST - 1 year ago

Karyopharm Announces the Appointment of Lori Macomber as Chief Financial Officer

Dec 9, 2024, 8:00 AM EST - 1 year ago

Karyopharm Announces the Appointment of Brendan Strong as Senior Vice President of Investor Relations and Corporate Communications

Dec 3, 2024, 7:00 AM EST - 1 year ago

Karyopharm Therapeutics Provides Endometrial Cancer Program Update

Nov 25, 2024, 7:00 AM EST - 1 year ago

Karyopharm to Participate at the Piper Sandler 36th Annual Healthcare Conference

Nov 20, 2024, 4:05 PM EST - 1 year ago

Karyopharm Therapeutics Announces the Appointment of Chief Accounting Officer

Nov 18, 2024, 7:00 AM EST - 1 year ago

Karyopharm to Present Selinexor Data at the 66th American Society of Hematology Annual Meeting and Exposition

Nov 5, 2024, 7:30 PM EST - 1 year ago

Antengene to Present Results from Two Late-Stage Studies of Selinexor Signaling Potential Clinical Breakthrough at ASH 2024

Nov 5, 2024, 7:30 AM EST - 1 year ago

Karyopharm Reports Third Quarter 2024 Financial Results and Highlights Recent Company Progress

Oct 31, 2024, 8:00 AM EDT - 1 year ago

Karyopharm to Report Third Quarter 2024 Financial Results on November 5, 2024

Oct 31, 2024, 7:30 AM EDT - 1 year ago

Karyopharm Announces Favorable Change in Co-Primary Endpoint for Pivotal Phase 3 SENTRY Trial in Myelofibrosis

Oct 30, 2024, 4:30 PM EDT - 1 year ago

Karyopharm to Host Investor Event with Leading Myelofibrosis KOLs and Provide a Favorable Study Design Update on October 31, 2024

Oct 17, 2024, 10:35 PM EDT - 1 year ago

Antengene Announces XPOVIO® (selinexor) Approved for Its Third Indication in South Korea, Bringing Fresh Hope to Patients with MM in the Country

Sep 23, 2024, 5:00 AM EDT - 1 year ago

Antengene Announces XPOVIO® (selinexor) Approved for Commercialization in Thailand

Sep 3, 2024, 7:00 AM EDT - 1 year ago

Karyopharm to Participate at Upcoming Investor Conferences

Aug 6, 2024, 7:30 AM EDT - 1 year ago

Karyopharm Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress

Aug 5, 2024, 8:00 PM EDT - 1 year ago

Antengene Announces XPOVIO® (selinexor) Approved for Commercialization in Malaysia

Jul 31, 2024, 4:05 PM EDT - 1 year ago

Karyopharm to Report Second Quarter 2024 Financial Results on August 6, 2024

Jul 5, 2024, 9:10 AM EDT - 1 year ago

XPOVIO® (selinexor) Approved for New Indication in DLBCL in China, Bringing a New Treatment Option to Patients in the Country

Jun 26, 2024, 4:42 AM EDT - 1 year ago

Antengene Announces XPOVIO® (selinexor) National Health Insurance Service Approval for Reimbursement in South Korea

Jun 1, 2024, 1:45 PM EDT - 2 years ago

Karyopharm Presents Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer During 2024 ASCO Plenary Series: Rapid Abstract Updates

May 29, 2024, 4:05 PM EDT - 2 years ago

Karyopharm to Participate at the Jefferies Global Healthcare Conference

celebratelife Apr. 9 at 4:18 AM

0 · Reply

hegdaom Apr. 9 at 3:24 AM

$KPTI

0 · Reply

hegdaom Apr. 9 at 3:24 AM

$KPTI $XBI

0 · Reply

ripztrip Apr. 9 at 1:18 AM

$KPTI This is running out of steam. Without big buyers this & next week, IMHO it's back at five or below soon! $XBI

0 · Reply

hegdaom Apr. 8 at 11:42 AM

$KPTI 5 or more years of dilution.

0 · Reply

hegdaom Apr. 8 at 6:14 AM

$KPTI Went up 36% in 5 sessions

0 · Reply

hegdaom Apr. 8 at 1:18 AM

$KPTI

1 · Reply

InkaTwits Apr. 7 at 6:29 PM

$KPTI 🤷‍♂️

0 · Reply

hbkstockislife Apr. 7 at 5:41 PM

$KPTI everyday up

1 · Reply

hegdaom Apr. 7 at 5:30 PM

$KPTI Any updates today?

0 · Reply

hegdaom Apr. 7 at 3:32 PM

$KPTI Even if Selinexor gets listed in NCCN guidelines: NCCN inclusion often includes lower-category recommendations (e.g., 2A, 2B) Physicians do not blindly follow NCCN—they prioritize: survival benefit (OS > PFS) tolerability familiarity with regimen payer friction 👉 So “in NCCN” ≠ meaningful market share.

1 · Reply

mich1282 Apr. 6 at 3:16 PM

$KPTI a KOL stating that Selinexor could take 30-40% of 1L via NCCN is not thinking

3 · Reply

hegdaom Apr. 6 at 2:13 PM

$KPTI Rising on nothing, it will also fall on nothing haha!

0 · Reply

WallStreetBuyDip Apr. 6 at 12:26 AM

same strategy as always for $KPTI - waiting for H% to show low

0 · Reply

celebratelife Apr. 5 at 11:18 PM

$KPTI Now suck on that Richie, Mikee; truth is bitter. Year after year of "Shareholders for insiders" is not enough, you even give away our funds - money we don't have - which illustrates ZERO ETHICS to abide by your mandate to create value. With an MBA Richie should understand what that means, or the Canadian school that gave him an MBA should close its doors. Year after year of effectively saying FUCK YOU to us shareholders as you arrogantly wasted our cash, splurged, got paid big bucks, allegedly breached your duties, and even gave away our cash with ZERO ETHICS to think bottom line, driving value, things you were hired to do.

0 · Reply

celebratelife Apr. 5 at 11:12 PM

$KPTI Lousy CEO Richard Paulson, Lousy GC Mike Mano, Lousy Board of Directors (Barry E. Greene, Garen Bohlin, Chen Schor, Deepa R. Pakianathan, Christy J. Oliger, Dr. Zhen Su - and former director Mansoor Mirza): gifts to shareholders - dream come true lousy team for short sellers who've made millions at shareholder cost because the above have allegedly breached their duties and bleached the shareholders off their cash in the form of value destruction which happens when you are lousy CEO/GC/Board and crooks know they can bet against you because they know you will keep fucking up as you have year after year while you destroyed over a billion dollars in value -- while yourselves made millions. Bitter truth. You forgot accountability and thought this vacation club culture is just there to give to YOU. I hear Mano barking. They don't like their profitable gig for themselves funded by us shareholders questioned. Their "vacation club" that keeps giving, to them, at our cost.

1 · Reply

russfa Apr. 2 at 9:07 PM

$KPTI unfortunately, karma is a fiction so there will be no more comeuppance for the crooked crew at Karyopharm than for the fat orange mafioso at the White House.

0 · Reply

celebratelife Apr. 2 at 9:01 PM

$KPTI Looks like they diluted us for pennies on the dollar to some hedge fund again. Instead of financial discipline for 5 years, Richard Paulson splurged our money, and even fucking gave it away to likes of Dempsey organization because he fucking thinks he's running a fucking charity instead of a for-profit-business -- except that it's FOR HIS PROFIT -- he's been compensated over $25 mil - probably over 30 mil by now after having destroyed and debilitated KPTI by incompetent (or compromised) mismanagement. And the fucking Board: Mansoor Mirza (for years), Barry E. Greene, Garen Bohlin, Chen Schor, Deepa R. Pakianathan, Christy J. Oliger, Zhen Su, sat there doing not jack shit about it -- they fucking just collected fucking big salary and bonuses for doing jack shit!! And this mess funded by us shareholders who trusted this gang - just because we believe in the science and was expecting that the fucking Board and management we hired would do their job which they haven't.

1 · Reply

celebratelife Apr. 2 at 4:42 PM

$KPTI 13,000 buy made it jump to 6.10 -- firing Richard Paulson and Mike Mano and that horrific Chairman Barry Greene and the rest of the useless Board will make it jump to $61.

0 · Reply

hegdaom Apr. 2 at 3:09 PM

$KPTI Ready to dump again EOD towards 5.5 and below

0 · Reply

celebratelife Apr. 1 at 8:03 PM

$KPTI Some good buying, which makes sense since there's every sign shorts are over-extended.

0 · Reply

FeliciaMath Apr. 1 at 5:52 PM

$KPTI sold today at 5.46. lost $60

2 · Reply

Market Cap	132.26M
Revenue (ttm)	146.07M
Net Income (ttm)	-196.04M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-134.21%
Debt to Equity Ratio	-0.40

Volume	487,200
Avg Vol	1,123,216
Day's Range	N/A - N/A
Shares Out	18.34M
Stochastic %K	83%
Beta	0.40
Analysts	Strong Sell
Price Target	$14.43